We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

316 hedge funds and large institutions have $2.06B invested in Recursion Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 86 funds opening new positions, 114 increasing their positions, 62 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more first-time investments, than exits

New positions opened: 86 | Existing positions closed: 34

84% more repeat investments, than reductions

Existing positions increased: 114 | Existing positions reduced: 62

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

18% more funds holding

Funds holding: 267 → 316 (+49)

18% more capital invested

Capital invested by funds: $1.74B → $2.06B (+$317M)

1% less call options, than puts

Call options by funds: $30.7M | Put options by funds: $30.9M

14.8% less ownership

Funds ownership: 94.22% → 79.42% (-15%)

Holders
316
Holders Change
+49
Holders Change %
+18.35%
% of All Funds
4.16%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
86
Increased
114
Reduced
62
Closed
34
Calls
$30.7M
Puts
$30.9M
Net Calls
-$211K
Net Calls Change
+$8.19M

Top Buyers

1
SoftBank Group
SoftBank Group
Japan
+$98.6M
2
NHAS
Novo Holdings A/S
Denmark
+$68M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$65.5M
4
BlackRock
BlackRock
New York
+$18.1M
5
Citadel Advisors
Citadel Advisors
Florida
+$16.8M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$51.5M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.68M
3
Voloridge Investment Management
Voloridge Investment Management
Florida
-$6.42M
4
NAMA
Nikko Asset Management Americas
New York
-$5.29M
5
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
-$5.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
26
Deerfield Management
New York
$15.6M – – –
Charles Schwab
27
Charles Schwab
California
$15.4M +$2.24M +333,323 +17%
UBS AM
28
UBS AM
Illinois
$15.3M +$796K +118,428 +6%
Goldman Sachs
29
Goldman Sachs
New York
$14M +$3.53M +525,504 +34%
Dimensional Fund Advisors
30
Dimensional Fund Advisors
Texas
$11.5M -$65.5K -9,739 -0.6%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$11.3M +$4.02M +597,390 +56%
Two Sigma Investments
32
Two Sigma Investments
New York
$11.2M +$425K +63,211 +4%
N
33
Nuveen
North Carolina
$7.23M -$362K -53,835 -5%
JP Morgan Chase
34
JP Morgan Chase
New York
$7.15M -$800K -119,024 -10%
CFM
35
Comprehensive Financial Management
California
$6.37M – – –
VAS
36
Vestmark Advisory Solutions
Massachusetts
$6.36M +$754K +112,221 +15%
LIP
37
Liontrust Investment Partners
United Kingdom
$6.3M -$392K -58,273 -6%
Bank of America
38
Bank of America
North Carolina
$5.97M -$1.9M -282,561 -24%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$5.75M -$507K -75,482 -8%
PIM
40
Platinum Investment Management
Australia
$4.96M +$3.68M +546,929 +294%
WP
41
Woodline Partners
California
$4.54M -$3.04K -452 -0.1%
NFGH
42
Nan Fung Group Holdings
Hong Kong
$4.49M +$4.47M +664,610 New
Barclays
43
Barclays
United Kingdom
$4.28M -$432K -64,307 -9%
PBPIA
44
Pivotal bioVenture Partners Investment Advisor
California
$4.03M +$4M +595,518 New
Rafferty Asset Management
45
Rafferty Asset Management
New York
$4.03M -$540K -80,319 -12%
IFWM
46
Institute for Wealth Management
Colorado
$3.93M +$3.91M +580,997 New
Lazard Asset Management
47
Lazard Asset Management
New York
$3.76M -$581K -86,458 -13%
Citigroup
48
Citigroup
New York
$3.39M +$2.09M +310,236 +163%
Swiss National Bank
49
Swiss National Bank
Switzerland
$3.29M +$871K +129,600 +36%
Wells Fargo
50
Wells Fargo
California
$3.1M +$2.31M +343,304 +298%
1
2
3 4 5

RXRX Hedge Fund Activity: Q4 2024 in Review

316 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2024, worth a combined $2.06B — up 18% from $1.74B a quarter earlier.

Buyers outnumbered sellers: 86 funds opened new RXRX positions and 34 closed out — a net gain of 52 holders — while 114 added to existing stakes and 62 trimmed.

The largest buyer was SoftBank Group, opening a new position worth an estimated $98.6M. The largest seller was RA Capital Management, cutting an estimated $51.5M.

  • 316 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2024, up from 267 in Q3 2024.
  • Funds reported $2.06B of Recursion Pharmaceuticals stock for Q4 2024, up 18% quarter-over-quarter.
  • 86 funds opened new Recursion Pharmaceuticals positions in Q4 2024 and 34 closed out, a net change of +52 holders.
  • The largest Recursion Pharmaceuticals buyer in Q4 2024 was SoftBank Group, an estimated $98.6M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2024 was RA Capital Management, an estimated $51.5M sold.

Based on aggregated 13F filings for Q4 2024.